Jasper Therapeutics price target lowered to $65 from $80 at Oppenheimer

Oppenheimer lowered the firm’s price target on Jasper Therapeutics (JSPR) to $65 from $80 and keeps an Outperform rating on the shares following quarterly results. Most important, Jasper now expects to provide updates from additional patients enrolled in the BEACON CSU study in the first half of Q3 vs. its prior mid-2025 guidance, which represents a key catalyst. In addition, Jasper plans to report data from additional patients enrolled in the SPOTLIGHT CIndU study at EAACI. Last, initial data from the ETESIAN Phase 1b/2a allergen challenge study remain on track to read out in the second half of the year, as the trial enrollment continues, Oppenheimer adds.